Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 10, Issue 1, 2003, Pages 1-7

  Hoffart, V ^a   Ubrich, N ^a   Lamprecht, A ^b   Bachelier, K ^a   Vigneron, C ^a   Lecompte, T ^c   Hoffman, M ^a   Maincent, P ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c CHU NANCY BRABOIS   (France)

Author keywords

Eudragit; Low Molecular Weight Heparin; Microparticles; PLGA; Poly caprolactone

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DRUG CARRIER; EUDRAGIT; FLUORESCEIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; POLYCAPROLACTONE; POLYCATION; POLYGLACTIN; POLYMER; STACHROM HEPARIN; TINZAPARIN;

ARTICLE; BIODEGRADABILITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG INJECTION VOLUME; DRUG RELEASE; DRUG TRANSPORT; EMULSION; FRACTIONATION; HEPARINIZATION; HUMAN; INFECTION; MICROENCAPSULATION; MICROPARTICLE ENZYME IMMUNOASSAY; MOLECULAR WEIGHT; PARTICLE SIZE; PATIENT SATISFACTION; POLYMERIZATION; PRIORITY JOURNAL; SURFACE CHARGE; THROMBOSIS;

EID: 0037275872     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/713840325     Document Type: Article

References (25)

1. Aftabrouchard, S., and Doelker, E. 1994. Factors influencing the entrapment of a water soluble model drug into injectable microparticles prepared using solvent evaporation and phase separation techniques. Eur. J. Pharm. Biopharm. 40(4):237-242.
2. Ageno, W. 2000. Treatment of venous thromboembolism. Thromb. Res. 97:V63-V72.
3. Ardry, M. 1967. Dosage de l'héparine: Étude critique. Bull. Ordre 135:699-708.
4. Boneu, B. 2000. Low molecular weight heparins: Are they superior to unfractionated heparins to prevent and treat deep vein thrombosis? Thromb. Res. 100:V113-V120.
5. Baughman, R. A., Kapoor, S. C., Agarwal, R. K., Kisicki, J., Catella-Lawson, F., and FitzGerald, G. A. 1998. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 98:1610-1615.
6. Clausen, A. E., and Bernkop-Schnürch, A. 2000. In vitro evaluation of the permeation enhancing effect of thiolated polycarbophil. J. Pharm. Sci. 89:1253-1261.
7. DalPozzo, A., Acquasaliente, M., and Geron, M. R. 1989. New heparin complexes active by intestinal absorption, I: Multiple ion pairs with basic organic compounds. Thromb. Res. 56:119-124.
8. Eldridge, J. H., Hammond, C. J., Meulbroek, J. A., Staas, J. K., Gilley, R., and Tice, T. R. 1990. Controlled vaccine release in the gut-associate lymphoid tissues. I - Orally administered biodegradable microspheres target the Peyer's patches. J. Controlled Rel. 11:205-214.
9. Gonze, M. D., Salartash, K., Sternbergh III W. C., Baughman, R. A., Leone-Bay, A., and Money, S. R. 2000. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 101:2658-2661.
10. Harrison, L., McGinnis, J., Crowther, M., Ginsberg, J., and Hirsh, J. 1998. Assessment of outpatient treatment of deep vein thrombosis with low molecular weight heparin. Arch. Intern. Med. 158:2001-2003.
11. Hirsh, J. 1991. Drug therapy. Heparin. N. Engl. J. Med. 324:1565-1574.
12. Hyers, T. M., Agnelli, G., Hull, R., Weg, J. G., Morris, T. A., Samama, M., and Tapson, V. 1998. Antithrombotic therapy for venous thromboembolic disease. Chest 114:561S-578S.
13. Jameela, S. R., Suma, N., and Jayakrishnan, A. 1997. Protein release from poly(ε-caprolactone) microspheres prepared by melt encapsulation and solvent evaporation techniques: A comparative study. J. Biomat. Sci. Polymer 8(6):457-466.
14. Jiao, Y., Ubrich, N., Marchand-Arvier, M., Vigneron, C., Hoffman, M., and Maincent, P. 2001. Preparation and in vitro evaluation of heparin-loaded polymeric nanoparticles. Drug Del. 8:135-141.
15. Jiao, Y., Ubrich, N., Hoffart, V., Marchand-Arvier, M., Vigneron, C., Hoffman, M., and Maincent, P. 2002a. Preparation and characterization of heparin-loaded polymeric microparticles. Drug Dev. Ind. Pharm. 28(8):1033-1041.
16. Jiao, Y., Ubrich, N., Hoffart, V., Marchand-Arvier, M., Vigneron, C., Hoffman, M., and Maincent, P. 2002b. Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J. Pharm. Sci. 91:1-9.
17. Jiao, Y., Ubrich, N., Marchand-Arvier, M., Vigneron, C., Hoffman, M., Lecompte, T., and Maincent, P. 2002c. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105:230-235.
18. Leone-Bay, A., Leipold, H., Agarwal, R., Rivera, T., and Baughman, R. A. 1997. The evolution of an oral heparin dosing solution. Drugs of the Future 22(8): 885-891.
19. Leone-Bay, A., Paton, D. R., Variano, B., Leipold, H., Rivera, T., Miura-Fraboni, J., Baughman, R. A., and Santiago, N. 1998. Acylated non-a-amino acids as novel agents for the oral delivery of heparin sodium, USP. J. Cont. Rel. 50:41-49.
20. Money, S. R., and York, J. W. 2001. Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis. Cardiovasc. Surg. 9(3):211-218.
21. Okada, H., Doken, Y., Ogawa, Y., and Toguchi, T. 1994. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm. Res. 11:1143-1147.
22. Rivera, T. M., Leone-Bay, A., Paton, D. R., Leipold, H. R., and Baughman, R. A. 1997. Oral delivery of heparin with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: Pharmacological considerations. Pharm. Res. 14(12):1830-1834.
23. Steiner, S., and Rosen, R. 1990. Delivery system for pharmacological agents encapsulated with proteinoids. U.S. patent 4925673.
24. Teien, A. N., and Lie, M. 1977. Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb. Res. 10:399-410.
25. Wells, P. S., Kovacs, M. J., Bormanis, J., Forgie, M. A., Goudie, D., Morrow, B., and Kovacs, J. 1998. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin. Arch. Intem. Med. 158:1809-1812.